CLDI Stock Analysis: Buy, Sell, or Hold?
CLDI - Calidi Biotherapeutics, Inc.
$0.17
-0.01 (-8.05%)
▼
5d:
-13.3%
30d:
-21.89%
90d:
-79.16%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When CLDI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CLDI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CLDI is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CLDI is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLDI is currently trading at $0.17, which is considered oversold relative to its 30-day fair value range of $0.18 to $0.22.
Technical Outlook: Technically, CLDI is in a strong downtrend. The price is currently testing key support at $0.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $120.00 (+72366.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLDI is in a strong downtrend. The price is currently testing key support at $0.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $120.00 (+72366.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.18 -
$0.22
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.1%)
- BULLISH: Trading 72366.7% below Wall St target ($120.00)
- WARNING: Recommendation downgraded due to -13.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.18 -
$0.22
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.17
Resistance Level
$0.20
Current Trend
Strong Downtrend
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.03
Wall Street Target
$120.00
(+72366.7%)
Share & Embed Analysis
Last updated: June 03, 2026 5:30 PM ET
Data refreshes hourly during market hours. Next update: 6:30 PM
Data refreshes hourly during market hours. Next update: 6:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLDI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Allan Camaisa
SELL
850 shares
2025-12-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 50 HOLD |
